GTAM
BDTX icon

Global Trust Asset Management’s Black Diamond Therapeutics BDTX Stock Holding History

Global Trust Asset Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-634
Closed -$1K – 423
2022
Q3 		$1K Buy
+634
New +$1.96K ﹤0.01% 411

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Global Trust Asset Management's BDTX Position: Q4 2022 in Review

Global Trust Asset Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2022, closing a stake of 634 shares — an estimated $1K sold.

Global Trust Asset Management first reported a position in BDTX in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 59 funds tracked by Wall St. Rank hold BDTX as of Q4 2022.

  • Global Trust Asset Management reported no remaining Black Diamond Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Global Trust Asset Management sold 634 Black Diamond Therapeutics shares in Q4 2022, an estimated $1K.
  • Global Trust Asset Management first reported a position in Black Diamond Therapeutics in Q3 2022 and held it in 1 quarter.
  • Global Trust Asset Management's Black Diamond Therapeutics position peaked at $1K in Q3 2022.
  • 59 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2022.

Based on Global Trust Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.